• 06 - DESTINY

  • Jun 28 2024
  • Length: 5 mins
  • Podcast

06 - DESTINY By cover art

06 - DESTINY

Listen for free

View show details

  • Summary

  • Con i nuovi risultati degli studi DESTINY sembra proprio che le prospettive per gli anticorpi coniugati debbano cambiare: dallo sfruttamento di target sovraespressi (HER2 nel caso specifico), alla comprensione del ruolo di minime espressioni e allo sviluppo - proprio del tipo “tumor agnostic” - in caso di mutazioni attivanti presenti in neoplasie diverse.

    Bibliografia

    • Curigliano G, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). 2024 ASCO Annual Meeting. Abstract LBA1000.
    • Li BT, et al; DESTINY-PanTumor01 study group. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol 2024:707-719.
    Show more Show less
activate_primeday_promo_in_buybox_DT
Hygiene & Healthy Living
Show more Show less

What listeners say about 06 - DESTINY

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available